Evidence map›Paper›PMID 38096790›Full record

ArticleCell host & microbe2023

Vivax malaria and Duffy antigen: Stop being so negative.

Patrick E Duffy, Karthigayan Gunalan, Louis H Miller

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell host & microbe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Human genetic variations conferring resistance to malaria.Journal of translational medicine · 2025
    Review
  2. Blood group antigens and malaria susceptibility.Frontiers in cellular and infection microbiology · 2025
    Review
  3. Malaria vaccines: a new era of prevention and control.Nature reviews. Microbiology · 2024
    Review
  4. Article
  5. Review
  6. Complement receptor 1 is the human erythrocyte receptor forProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Patrick E DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA. Electronic address: patrick.duffy@nih.gov.
Karthigayan GunalanLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA.
Louis H MillerLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA.
National Institute of Allergy and Infectious Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duffy blood group antigen (Duffy antigen/receptor for chemokines, atypical chemokine receptor-1, Duffy antigen), an essential Plasmodium vivax invasion receptor, is absent in most Africans. In this issue, two papers show erythroid precursors from Duffy-negative individuals transiently surface-express Duffy antigen and support vivax infection, potentially explaining low-density vivax infections across Africa.

Indexed as

Malaria, VivaxDuffy Blood-Group SystemErythrocytesHumansPlasmodium vivaxProtozoan ProteinsDuffy Blood-Group SystemProtozoan Proteins

Identifiers

PMID38096790
OpenAlexW4389672563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.